StockData
Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc. (CRBU) stock

CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3078% below fair value
$0.28−0.03 (-8.44%)

Close on Nov 20, 2026Market cap $30.48MP/E –Yield –

Caribou Biosciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Caribou Biosciences's free cash flow for the twelve months ending Jun 30, 2026 was -$95.75M. For fiscal 2025 it was -$112.35M. The highest annual figure on record is -$32.89M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$112.35M–
FY2024Dec 31, 2024-$143.08M–
FY2023Dec 31, 2023-$104.90M–
FY2022Dec 31, 2022-$97.42M–
FY2021Dec 31, 2021-$34.64M–
FY2020Dec 31, 2020-$33.53M–
FY2019Dec 31, 2019-$32.89M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$22.79M–
Q1 FY2026Mar 31, 2026-$27.06M–
Q4 FY2025Dec 31, 2025-$20.61M–
Q3 FY2025Sep 30, 2025-$25.30M–
Q2 FY2025Jun 30, 2025-$28.68M–
Q1 FY2025Mar 31, 2025-$37.77M–
Q4 FY2024Dec 31, 2024-$35.99M–
Q3 FY2024Sep 30, 2024-$33.33M–
Q2 FY2024Jun 30, 2024-$35.11M–
Q1 FY2024Mar 31, 2024-$38.65M–
Q4 FY2023Dec 31, 2023-$23.66M–
Q3 FY2023Sep 30, 2023-$33.54M–
Q2 FY2023Jun 30, 2023-$17.74M–
Q1 FY2023Mar 31, 2023-$29.97M–
Q4 FY2022Dec 31, 2022-$26.80M–
Q3 FY2022Sep 30, 2022-$23.73M–
Q2 FY2022Jun 30, 2022-$24.49M–
Q1 FY2022Mar 31, 2022-$22.40M-210.4%
Q4 FY2021Dec 31, 2021-$22.07M–
Q3 FY2021Sep 30, 2021-$15.90M–
Q2 FY2021Jun 30, 2021-$16.96M–
Q1 FY2021Mar 31, 2021$20.29M–
Q4 FY2020Dec 31, 2020-$8.10M–
Q3 FY2020Sep 30, 2020-$8.71M–

More Caribou Biosciences figures

See a number that looks wrong?